Melatonin Dosing Recommendations for REM‑Sleep Behavior Disorder

Titration Strategy

• The American Academy of Sleep Medicine (AASM) guideline advises titrating melatonin in 3 mg increments for REM‑sleep behavior disorder (RBD), starting from a 4 mg nightly dose and increasing to 6–7 mg, with the option to continue increments up to a maximum of 15 mg; this approach is described as the evidence‑based standard, although data on doses above 15 mg are lacking. 1

Formulation Selection

• Only immediate‑release melatonin formulations are recommended for RBD, because prolonged‑release products lack sufficient supporting evidence. 1
• When selecting a dietary‑supplement melatonin product in the United States or Canada, choose one bearing the U.S. Pharmacopeia Verification Mark to ensure the label‑stated dose is accurate. 1

Escalation Beyond 6–7 mg

• If an adequate clinical response is not achieved at 6–7 mg, clinicians commonly add clonazepam as combination therapy before considering further melatonin dose escalation to the 9–15 mg range. 1
• Evidence regarding the safety and efficacy of melatonin + clonazepam combination therapy remains limited. 1

Monitoring and Follow‑Up

• Patients should be reassessed after 1–2 weeks of a new melatonin dose to evaluate therapeutic response. 1
• Clinicians should monitor for next‑day sedation or cognitive effects; such adverse events are uncommon with melatonin and occur less frequently than with benzodiazepines. 1
• Therapeutic effects of melatonin typically persist for several days after discontinuation, with symptom return occurring gradually over subsequent weeks. 1